Literature DB >> 22564244

Itraconazole inhibits HMEC-1 angiogenesis.

Renata Del Carratore1, Angelo Carpi, Pascale Beffy, Valter Lubrano, Lucia Giorgetti, Bianca Elena Maserti, Maria Annunziata Carluccio, Marcella Simili, Giorgio Iervasi, Silvana Balzan.   

Abstract

Abnormal angiogenesis is implicated in a number of human diseases and endothelial growth inhibition represents a common approach in tumor therapy. Recently itraconazole, frequently used in humans as antifungal drug, which blocks the biosynthesis of cholesterol, has been found to be antiangiogenic in primary umbilical vein endothelial cells. However, the exact antiangiogenic mechanisms remain largely unknown. In this paper, we studied the effect of itraconazole in human dermal microvascular endothelial cells (HMEC-1), an immortalized cell line to study adult angiogenesis. A 50% reduction of microtubule formation was observed after itraconazole treatment which was partially rescued by cholesterol addition. We found that itraconazole inhibits angiogenesis markers such as VEGF, AAMP and e-NOS. mTOR and ERK1/2 phosphorylation as well as the expression of Gli1, one of the main controllers of the Shh pathway, were also inhibited by itraconazole. Cholesterol addition did not completely rescue inhibition of these pathways, suggesting that the itraconazole antiangiogenic activity could be due to multiple mechanisms. Our results may contribute to novel approaches to block angiogenesis with therapeutic application.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22564244     DOI: 10.1016/j.biopha.2011.11.004

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole.

Authors:  Katharina R Beck; Murielle Bächler; Anna Vuorinen; Sandra Wagner; Muhammad Akram; Ulrich Griesser; Veronika Temml; Petra Klusonova; Hideaki Yamaguchi; Daniela Schuster; Alex Odermatt
Journal:  Biochem Pharmacol       Date:  2017-01-25       Impact factor: 5.858

2.  Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors.

Authors:  Michael L Garelja; Maggie Au; Margaret A Brimble; Joseph J Gingell; Erica R Hendrikse; Annie Lovell; Nicole Prodan; Patrick M Sexton; Andrew Siow; Christopher S Walker; Harriet A Watkins; Geoffrey M Williams; Denise Wootten; Sung H Yang; Paul W R Harris; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-26

3.  Intravitreal itraconazole inhibits laser-induced choroidal neovascularization in rats.

Authors:  Jeong Hun Bae; Ah Reum Hwang; Chan Yun Kim; Hyeong Gon Yu; Hyoung Jun Koh; Woo Ick Yang; Hae Ran Chang; Sung Chul Lee
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

4.  Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways.

Authors:  Guanzhao Liang; Musang Liu; Qiong Wang; Yongnian Shen; Huan Mei; Dongmei Li; Weida Liu
Journal:  Oncotarget       Date:  2017-04-25

5.  Co-Delivery of Repurposing Itraconazole and VEGF siRNA by Composite Nanoparticulate System for Collaborative Anti-Angiogenesis and Anti-Tumor Efficacy against Breast Cancer.

Authors:  Mingji Jin; Bowen Zeng; Yanhong Liu; Lili Jin; Yan Hou; Chao Liu; Wei Liu; Hao Wu; Liqing Chen; Zhonggao Gao; Wei Huang
Journal:  Pharmaceutics       Date:  2022-06-28       Impact factor: 6.525

Review 6.  Pediatric medulloblastoma - update on molecular classification driving targeted therapies.

Authors:  Ruth-Mary DeSouza; Benjamin R T Jones; Stephen P Lowis; Kathreena M Kurian
Journal:  Front Oncol       Date:  2014-07-22       Impact factor: 6.244

7.  The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.

Authors:  Federica Maione; Simonetta Oliaro-Bosso; Claudia Meda; Federica Di Nicolantonio; Federico Bussolino; Gianni Balliano; Franca Viola; Enrico Giraudo
Journal:  Sci Rep       Date:  2015-03-12       Impact factor: 4.379

8.  SMYD1, an SRF-Interacting Partner, Is Involved in Angiogenesis.

Authors:  Xiangli Ye; Yu Qian; Qian Wang; Wuzhou Yuan; Xiaoyang Mo; Yongqing Li; Zhigang Jiang; Wei Xu; Yun Deng; Yongqi Wan; Xiongwei Fan; Xiushan Wu; Yuequn Wang
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.